• Ceapin-A7: Selective ER Stress Blocker for Precision Pathway

  2026-04-30

  Ceapin-A7 stands out as a selective ER stress blocker, enabling researchers to modulate the ATF6α pathway with unmatched specificity. Its robust performance in unfolded protein response studies, along with clear protocol guidance, supports advanced disease modeling and mechanism dissection.

• L-NAME Hydrochloride in Translational CI-AKI and Apoptosis R

  2026-04-30

  Explore the advanced applications of L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) in apoptosis and inflammation signaling modulation, with a unique focus on acute kidney injury models and translational assay design. Discover how APExBIO’s reagent supports cutting-edge vascular and renal research.

• Anti-Fibrotic Effects of 1-Phenyl-2-Pentanol on Hepatic Stel

  2026-04-29

  This study identifies 1-phenyl-2-pentanol, a compound from Moringa oleifera, as a potent inhibitor of hepatic stellate cell activation and fibrogenic signaling in vitro. By elucidating its mechanism—targeting both TGF-β1 and Wnt/β-catenin pathways—the research offers new directions for anti-fibrotic drug development.

• Hexetidine (NSC-17764): Reliable Biofilm & Oral Antimicrobia

  2026-04-29

  This article provides laboratory researchers with scenario-driven guidance on leveraging Hexetidine (NSC-17764), SKU BA1327, as a robust, reproducible solution for biofilm inhibition, oral infection models, and cell-based assays. Integrating literature-backed data, real-world troubleshooting, and vendor selection advice, the piece empowers scientific decision-making and highlights APExBIO’s Hexetidine for sensitive, evidence-driven workflows.

• YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol: Techn

  2026-04-28

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol enables targeted inhibition of hypoxia-inducible factor 1 transcriptional activity and sGC activation in cancer and vascular biology workflows. This reagent is best suited for in vitro and in vivo models requiring precise modulation of HIF-1α or cGMP signaling. Use is restricted to scientific research and not for diagnostic or clinical applications.

• Migratory Interneuron Therapy for Glioblastoma: A Mechanisti

  2026-04-28

  Brosius et al. demonstrate that modified cortical interneuron precursors (MCIPs) can migrate to high-grade glioma and locally deliver bispecific T-cell engagers, prolonging survival in mouse models. This strategy addresses therapeutic delivery challenges in glioblastoma and establishes a novel cellular vector with translational potential.

• GOT1 Inhibition by Ziprasidone Reprograms Redox in Pancreati

  2026-04-27

  Yang et al. (2022) demonstrate that ziprasidone acts as a non-competitive inhibitor of GOT1, disrupting glutamine metabolism and redox homeostasis in pancreatic ductal adenocarcinoma (PDAC) cells. Their findings reveal GOT1 as a metabolic vulnerability in PDAC and suggest new experimental directions for targeting tumor redox regulation.

• Notopterol Reprograms Macrophage Metabolism via α7nAChR in S

  2026-04-27

  The referenced study uncovers that Notopterol, a natural compound, alleviates synovitis by promoting anti-inflammatory macrophage polarization through α7 nicotinic acetylcholine receptor (α7nAChR)-dependent metabolic reprogramming. These findings shed light on targeting metabolic pathways in macrophages as a promising strategy for inflammatory arthritis intervention.

• Ibrexafungerp Efficacy Against Fluconazole-Resistant Candida

  2026-04-26

  Wiederhold et al. demonstrate that ibrexafungerp exhibits potent in vitro and in vivo activity against fluconazole-resistant Candida auris, including efficacy even when treatment is delayed. These findings highlight the urgent need for alternative antifungal agents and inform experimental strategies for modeling drug-resistant fungal infections.

• Bismuth Subsalicylate: Practical Guide for GI Disorder Resea

  2026-04-25

  Bismuth Subsalicylate (SKU A8382) addresses key challenges in gastrointestinal disorder research, particularly for studies on inflammation and diarrhea treatment. Its documented insolubility and storage requirements set clear boundaries for experimental design, making it best suited for workflows where solid-phase or suspension formats are acceptable. It should not be used in protocols requiring aqueous, ethanol, or DMSO solubility.

• Leptin (116-130), amide, mouse: Applied Protocols & Optimiza

  2026-04-24

  Leptin (116-130), amide, mouse, a potent adipocyte-derived hormone fragment, enables precise modeling of leptin signaling in metabolic disease research. This article details hands-on protocols, advanced assay use-cases, and troubleshooting strategies for robust experimental outcomes.

• Toremifene: Applied Protocols for Estrogen Receptor Modulato

  2026-04-24

  Toremifene, a potent second-generation selective estrogen-receptor modulator, is transforming prostate cancer research by enabling precise dissection of hormone and calcium signaling pathways. This article delivers actionable workflow enhancements and troubleshooting guidance, translating cutting-edge findings—like the TSPAN18-STIM1 axis—into practical assay design. Explore comparative advantages and future outlooks for leveraging Toremifene in translational cancer biology.

• Guanabenz Acetate: Precision α2-Adrenergic Modulation in Hos

  2026-04-23

  Explore how Guanabenz Acetate, a selective α2-adrenergic receptor agonist, enables advanced dissection of GPCR signaling and innate immune pathways. This article uniquely bridges receptor pharmacology with viral immune evasion research, supported by recent mechanistic findings.

• hiPSC-Derived Intestinal Organoids for CYP2C19 Metabolism St

  2026-04-23

  This study presents a streamlined protocol to generate human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) for pharmacokinetic evaluation, offering a more physiologically relevant in vitro model for drug metabolism studies than traditional systems. The organoids support robust cytochrome P450 enzyme activity, enabling accurate assessment of CYP2C19 substrate metabolism and advancing the study of oral drug biotransformation.

• Mutational Landscape of Myeloma Cell Lines: Insights for Dru

  2026-04-22

  This study delivers the first comprehensive exome-wide analysis of human multiple myeloma cell lines (HMCLs), identifying both established and novel genetic drivers of tumor progression and drug resistance. The findings provide a critical resource for selecting appropriate cell line models and inform strategies for targeted therapeutic research in hematological malignancy.

14559 records 1/971 page Next 12345 下5页 Last page